Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
De flinke stijging van het aantal nieuwe Corona besmettingen in verschillende Amerikaanse staten maakte beleggers enigszins nerveus, ook gelet op mogelijke lockdowns. Wie nu nog eens de opmerking gaat maken dat Pharming te laat komt met zijn Covid-19 Basel onderzoek moet maar gaan emigreren naar de States.......
zjeeraar schreef op 24 juni 2020 23:14 :
...
Wie nu nog eens de opmerking gaat maken dat Pharming te laat komt met zijn Covid-19 Basel onderzoek moet maar gaan emigreren naar de States.......
Dan wordt het rustig hier :)
Eric de Rus schreef op 24 juni 2020 22:41 :
[...]
Pech?? Heeft niks met pech te maken hoor.
Pharming bakt er gewoon niks van. Ja, bla bla chocoladevla en zwarte cijfers met puntjes van onnozele particulieren ;))
Pharming is niks meer of minder dan een kraslot. De uitgever van de krasloten wint altijd.
Daarom is Pharming zo'n mooi aandeel om short te gaan. Genoeg particulieren die dollartekens in hun ogen hebben en Pharming kopen.
200.000.000 omzet. Ja ze bakken er niks van. Bijna schuldloos. Ja ze bakken er niks van. Komen nog veel mooie dingen aan.
Nieuws: Oplaaiende corona aantallen in Amerika, Portugal en Duitsland.
homesecuur schreef op 25 juni 2020 06:35 :
Wat een gebasel hier
Aan de linkerzijde van het scherm staat heel vaak gebazel, aan de rechterzijde de feiten. Aan u de keuze wat u lezen wilt. Fijne dag, Tini
gaaaaaaaaaaaaaaaaaaaaaaap .......... succes met het afvangen van vliegen bij elkaar, en op naar het volgende zeer positieve persbericht ....................
Coulter Partners secures Supervisory Board Directors for Pharming Group Published: 24 Jun 2020 By Nola Cadman Coulter Partners secures Supervisory Board Directors for Pharming Group Coulter Partners was delighted to partner recently with Pharming Group N.V. (Euronext Amsterdam: PHARM), to secure the nomination of Barbara Yanni and Mark Pykett to the Board of Supervisory Directors. An Extraordinary General Meeting of Shareholders is expected to be convened later this year for their official appointment. Until that moment, Barbara Yanni and Mark Pykett will hold an observational role within Pharming’s Board of Supervisory Directors. Pharming Group N.V. is a specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs. Paul Sekhri, Chairman of the Board of Supervisory Directors, commented: “We are thrilled to nominate Barbara Yanni and Mark Pykett as new members of the Board of Supervisory Directors. Their extensive experience and strong track record in pharmaceuticals and biotechnology in the US complements the existing expertise of our Board. Accordingly, they will further strengthen the Board’s ability to effectively oversee Pharming’s fast-growing global business activities, especially those in the increasingly important US market and I thank the team at Coulter Partners for their professional support in achieving these key nominations.” Sijmen de Vries, Chief Executive Officer, added:“I welcome Barbara Yanni and Mark Pykett to Pharming. I look forward to working closely with them both, as we continue to implement our growth strategy from a strong financial position with additional cash resources to invest in the Company’s long-term prospects.” Barbara Yanni Barbara Yanni has over thirty-five years of experience in pharmaceuticals and biotechnology. She currently serves as an independent director of three public clinical-stage biopharmaceutical companies, including Trevena (NASDAQ: TRVN), Vaccinex (NASDAQ: VCNX) and Akcea (NASDAQ: AKCA). In the past, Barbara served as a board member of Abionyx (Paris: ABNX) and Symic Bio, a private biotech company. Barbara retired from Merck & Co., Inc. in 2014 after 12 years as Vice President and Chief Licensing Officer. At Merck, Barbara and her licensing team successfully structured and negotiated agreements to acquire rights to over 150 compounds, programs and technologies to enhance the pipeline. In addition, Barbara significantly increased Merck's visibility as a preferred partner. Barbara began her Merck career as a tax lawyer and then transitioned to finance, first as Director of Benefits Financing and subsequently as Senior Director of Financial Evaluations and Analysis where she evaluated the financial aspects of acquisitions, joint ventures, licenses and other transactions. Barbara has a JD from Stanford Law School and an AB from Wellesley College where she studied Physics and Latin. She also holds a Masters of Law in Taxation from New York University Mark Pykett Mark Pykett is Chief Scientific Officer of PTC Therapeutics (NASDAQ: PTCT). Before joining PTC in 2018, Mark held a number of executive positions, including president and Chief Executive Officer (CEO) of Agilis Biotherapeutics, CEO of Navidea Biopharmaceuticals (NYSE MKT: NAVB), and president and CEO of Alseres Pharmaceuticals (ALSE.PQ), among others. Mark also served as a director of several public and private companies, as well as the not-for-profit organisation, HealthBuilders, which develops health infrastructure in central Africa.Mark received his B.A. from Amherst College, a V.M.D. and Ph.D. from the University of Pennsylvania, and an M.B.A. from Northeastern University, and completed postdoctoral fellowships at the University of Pennsylvania and Harvard University. About Pharming Group N.V. Pharming is a specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs. Pharming’s lead product, RUCONEST® (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (“HAE”) attacks in patients in Europe, the US, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorisation. Additional information is available on the Pharming website: www.pharming.com About Coulter Partners Coulter Partners is a board and senior level executive search boutique focussed exclusively on global Life Sciences. From our offices in the UK, Europe, North America and Asia-Pacific, we work together across boundaries and disciplines to build outstanding leadership teams for our clients in the pharmaceuticals, biotechnology, medical devices, health tech, diagnostics, CRO and services sectors. Our industry leading reputation is founded on deep sector knowledge and innovative thinking. Our strategy is built on a unique team culture and true global reach. Our goal is to bring you the world’s best talent.
Theoretical Opening Price 1.1865 Goedemorgen allen!
Goede morgen, Hoe gaat het met Pharming? Ik heb al een tijdje niks meer van hem gehoord. Laatste PB 20 mei...
Elwin1980 schreef op 25 juni 2020 08:29 :
Goede morgen,
Hoe gaat het met Pharming?
Ik heb al een tijdje niks meer van hem gehoord.
Laatste PB 20 mei...
Staat Pharming in deze symbool voor een persoon? Best wel irritant die berichtjes van jou.
Marbella schreef op 25 juni 2020 08:33 :
[...]
Staat Pharming in deze symbool voor een persoon? Best wel irritant die berichtjes van jou.
Deze persoon doet zich dom voor of is echt dom. Stelt iedere keer retorische vragen.
Valt niet mee om een droge handdoek nog verder uit te wringen.
Dekkie schreef op 24 juni 2020 21:18 :
[...]
Gaan we oude koeien uit de sloot halen.
Klopt, en deze zal ik nog geregeld blijven delen. Het zijn veelal zelfbenoemde 'kenners' die nu bijna twee jaar na dato nog steeds mijlenver van de realiteit af liggen met hun euforistische koersdoelen die binnen een paar maanden zeker gehaald zouden worden. Beide beentjes aan de grond houden is het devies.
Vermogen schreef op 25 juni 2020 08:49 :
[...]
Deze persoon doet zich dom voor of is echt dom.
Stelt iedere keer retorische vragen.
Ah, ok. Ik zal me niet meer ergeren aan deze. ;-) De beursvloer op!
Vrees dat we vandaag weer 2 cent afzakken :(
Marbella schreef op 25 juni 2020 08:55 :
[...]
Ah, ok. Ik zal me niet meer ergeren aan deze. ;-) De beursvloer op!
Het zal gezellig worden vandaag gezien de pre-opening.
List en bedrog bij pharming of toch een spiegel die ze ons voorhouden
Zo lang er niks wordt gezegd vanuit het management van Pharming kunnen we makkelijk tot onder de 1,10 zakken. Simpelweg de grafiek aflezen tot een jaar geleden. Geduld is geboden met dit aandeel.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)